Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stock Watch: Where Novo And Lilly Lead, Others Follow

AstraZeneca Resurrects Its Metabolic Franchise

Executive Summary

AstraZeneca is the latest GLP-1 agonist aspirant after Novo’s and Lilly’s recent earnings season successes. Already, a segmentation of potential patients and frantic competition among new GLP-1 agonists and drug combinations are emerging.

You may also be interested in...

Stock Watch: After The Pandemic, Different Vaccines To The Rescue

From the unfavorable comparisons brought about by lower pandemic-related product sales, vaccines for other diseases bring hopes for longer-term success.

AstraZeneca CEO Soriot On Obesity, Gene Therapy And More

CEO Pascal Soriot fielded questions on a wide range of topics – from China to US Medicare drug price negotiations – at a media briefing in New York City.

AHA 2023 – Wegovy Cuts Death Risk, But Will That Be Enough For Payers?

The SELECT cardiovascular outcomes trial is a convincing hit; now Novo Nordisk must grapple with reimbursement and manufacturing.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts